Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L35 pseudogene 2 (RPL35P2) is classified as a *pseudogene* in the human genome, meaning it is a non-functional segment of DNA that resembles the functional ribosomal protein L35 gene but does not produce a functional protein product. It is not expressed as a protein and does not have known biological functions or roles in disease. Pseudogenes can arise from gene duplication or retrotransposition events but typically lack the capability to code for proteins due to accumulated mutations or lack of regulatory elements[3][2][6]. Thus, RPL35P2 is not considered a therapeutic target, is not involved in cellular pathways or processes, and has no known drug interactions. Supporting details: - RPL35P2 is explicitly denoted as a pseudogene in both the HUGO Gene Nomenclature Committee (HGNC) and GeneCards databases[2][3]. - There are no known aliases in major gene and protein nomenclature databases[2][3]. - There are no reported disease associations, biological functions, or pathway roles[3]. - It is not a druggable or therapeutic target; there are no known interacting drugs or mechanisms of action. - The label "pseudogene" places it outside classical molecular target classes such as receptor, enzyme, transporter, etc. Summary: RPL35P2 is a non-functional pseudogene. It does not encode a protein, participate in cellular functions, or serve as a target in therapeutic contexts[2][3][6].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L35 pseudogene 2 (RPL35P2).